Jpmorgan Chase & CO Dice Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$25.86 - $46.71 $14.8 Million - $26.7 Million	571,732 Added 1233.32%	618,089 $28.7 Million
Q1 2023 May 18, 2023	BUY	$26.05 - $32.31 $1.14 Million - $1.41 Million	43,689 Added 1637.52%	46,357 $1.33 Million
Q1 2023 May 11, 2023	SELL	$26.05 - $32.31 $909,509 - $1.13 Million	-34,914 Reduced 92.9%	2,668 $76,000
Q4 2022 Feb 13, 2023	BUY	$19.77 - $42.23 $251,632 - $537,503	12,728 Added 51.21%	37,582 $1.17 Million
Q3 2022 Nov 14, 2022	BUY	$14.97 - $22.65 $72,814 - $110,169	4,864 Added 24.33%	24,854 $504,000
Q2 2022 Aug 11, 2022	BUY	$13.19 - $22.1 $130,594 - $218,812	9,901 Added 98.14%	19,990 $311,000
Q1 2022 May 11, 2022	BUY	$14.54 - $25.02 $22,784 - $39,206	1,567 Added 18.39%	10,089 $193,000
Q4 2021 Feb 10, 2022	BUY	$22.41 - $37.54 $190,978 - $319,915	8,522 New	8,522 $215,000

17.7K

13K

Ticker DICE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,430,000
Description
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lea...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.